EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study

Jin-Ji Yang iD, Yan Zhang iD, Lin Wu iD, Jie Hu, Zhe-Hai Wang, Jing-Hua Chen, Yun Fan, Gen Lin, Qi-Ming Wang iD, Yu Yao, Jun Zhao, Yuan Chen und 11 weitere

Journal of Clinical Oncology · 2024-11 · 42 (31) · 3680-3691

DOI: 10.1200/jco.23.02363 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024-11. Verfasst von Jin-Ji Yang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Southern Medical University, Guang…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins c-met, Mutation. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The KUNPENG study aimed to evaluate the efficacy and safety of vebreltinib (also known as bozitinib, APL-101, PLB-1001, and CBT-101), a potent and highly selective inhibitor of c-mesenchymal-epithelial transition ( MET ), in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring c-Met alterations. METHODS This multicenter, multicohort, open-label, single-arm, phase II trial enrolled patients with c-Met dysregulated, locally advanced or metastatic NSCLC from January 2020 to August 2022 across 17 centers. Cohort 1 included patients with MET exon 14 skipping ( MET ex14)–mutant NSCLC who had not previously received MET inhibitors. Participants were administered vebreltinib at a dosage of 200 mg twice a day in 28-day cycles. The primary end point was the objective response rate (ORR), and the key secondary end point was the duration of response (DoR), both evaluated by a blinded independent review committee according to the RECIST version 1.1. RESULTS As of August 9, 2022, 52 patients had been enrolled in cohort 1, of whom 35 (67.3%) were treatment-naïve. The ORR reached 75% (95% CI, 61.1 to 86). Among treatment-naïve patients, the ORR was 77.1% (95% CI, 59.9 to 89.6), and in previously treated patients, it was 70.6% (95% CI, 44.0 to 89.7). The disease control rate was 96.2%, with a median DoR of 15.9 months, a median progression-free survival of 14.1 months, and a median overall survival of 20.7 months. The most common treatment-related adverse events were peripheral edema (82.7%), QT prolongation (30.8%), and elevated serum creatinine (28.8%). CONCLUSION Vebreltinib has shown promising efficacy and a favorable safety profile in patients with MET ex14-mutant NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-metMutationExonsHumansMaleFemaleMiddle AgedAgedAdultIndazolesProgression-Free SurvivalPyrazines

Substanzen

Proto-Oncogene Proteins c-metMET protein, humanIndazolesPyrazines

Autor:innen und Institutionen

  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
  • Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Thoracic Medical Oncology, Hunan Cancer Hospital, Changsha, China.
  • Pulmonary and Critical Care Medicine, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.
  • Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

ORCID-Profile: Jin-Ji Yang, Yan Zhang, Lin Wu, Qi-Ming Wang, Ying Cheng, Ren-Hua Guo, Di Han, Yi-Long Wu

Zitieren

APA

Yang, J. J., Zhang, Y., Wu, L., Hu, J., Wang, Z. H., Chen, J. H., Fan, Y., Lin, G., Wang, Q. M., Yao, Y., Zhao, J., Chen, Y., Fang, J., Song, Y., Zhang, W., Cheng, Y., Guo, R. H., Li, X. Y., Shi, H. P., …, & Wu, Y. L. (2024). Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study. Journal of Clinical Oncology, 42(31), 3680-3691. https://doi.org/10.1200/jco.23.02363

Vancouver

Yang JJ, Zhang Y, Wu L, Hu J, Wang ZH, Chen JH, et al. Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study. Journal of Clinical Oncology. 2024;42(31):3680-3691. doi:10.1200/jco.23.02363

BibTeX
@article{Yang2024,
  author = {Yang, Jin-Ji and Zhang, Yan and Wu, Lin and Hu, Jie and Wang, Zhe-Hai and Chen, Jing-Hua and Fan, Yun and Lin, Gen and Wang, Qi-Ming and Yao, Yu and Zhao, Jun and Chen, Yuan and Fang, Jian and Song, Yong and Zhang, Wei and Cheng, Ying and Guo, Ren-Hua and Li, Xing-Ya and Shi, He-Peng and Xue, Wei-Zhe and Han, Di and Zhang, Pei-Long and Wu, Yi-Long},
  title = {Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {31},
  pages = {3680--3691},
  doi = {10.1200/jco.23.02363}
}
Kostenlos starten →